Blood group antigens, Lewisx and Lewisy in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma
- PMID: 2817084
- PMCID: PMC1880090
Blood group antigens, Lewisx and Lewisy in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma
Abstract
Despite major advances in the differential diagnosis of mesotheliomas versus adenocarcinomas, a certain percentage defy diagnosis. Several markers such as keratin, carcinoembryonic antigen, Leu-M1, milk fat globulin, and antibody against tumor-associated glycoprotein Tag-72 (B72.3) have been used to distinguish them. In this study, blood group antigens, namely Lewisx and Lewisy, known to be expressed in a number of adenocarcinomas of diverse origin were used in the differential diagnosis of 30 samples from 18 mesotheliomas and 18 primary lung adenocarcinomas. Adenocarcinomas showed strong diffuse homogeneous staining, membranous staining, or both for Lewisy in 100% of cases irrespective of differentiation. Lewisx was expressed in 78% of adenocarcinomas with a wide variation in distribution of staining. Mesotheliomas did not show the diffuse homogeneous staining pattern but showed a markedly distinctive granular staining in the cytoplasm of rare cells in 23% of Lewisy and 20% of Lewisx cases, which was interpreted as negative. In conclusion, Lewisy is a sensitive marker for adenocarcinomas in that it stains 100% of cases and is a specific marker in the differential diagnosis of mesotheliomas and adenocarcinomas.
Similar articles
-
The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.Am J Surg Pathol. 1989 Apr;13(4):276-91. Am J Surg Pathol. 1989. PMID: 2648877
-
Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.Arch Pathol Lab Med. 1996 Oct;120(10):959-66. Arch Pathol Lab Med. 1996. PMID: 12046609
-
Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12.Am J Pathol. 1986 Jun;123(3):497-507. Am J Pathol. 1986. PMID: 3717302 Free PMC article.
-
[Immunohistochemistry of mesotheliomas. Technique and current diagnostic contribution of immunohistochemical markers. General review].Arch Anat Cytol Pathol. 1993;41(5-6):212-22. Arch Anat Cytol Pathol. 1993. PMID: 8135582 Review. French.
-
Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.Am J Clin Pathol. 1998 Jan;109(1):85-9. doi: 10.1093/ajcp/109.1.85. Am J Clin Pathol. 1998. PMID: 9426522 Review.
Cited by
-
Protein glycosylation in cancer biology: an overview.Clin Mol Pathol. 1996 Jun;49(3):M126-35. doi: 10.1136/mp.49.3.m126. Clin Mol Pathol. 1996. PMID: 16696060 Free PMC article. No abstract available.
-
Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.Fam Cancer. 2004;3(3-4):265-81. doi: 10.1007/s10689-004-9554-y. Fam Cancer. 2004. PMID: 15516851 Review.
-
Altered expression of sialyl-Tn, Lewis antigens and carcinoembryonic antigen between primary and metastatic lesions of uterine cervical cancers.Histochemistry. 1992 May;97(4):311-7. doi: 10.1007/BF00270031. Histochemistry. 1992. PMID: 1618644
-
Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: Immunohistochemical findings.Virchows Arch A Pathol Anat Histopathol. 1993;423(1):19-27. doi: 10.1007/BF01606427. Virchows Arch A Pathol Anat Histopathol. 1993. PMID: 8212530
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical